Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician-Reference-Cited by-同舟云学术

Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician

Published:2023-06-01 Issue:1 Volume:13 Page:91-101
ISSN:2411-4634
Container-title:Head and Neck Tumors (HNT)
language:
Short-container-title:Opuholi golovy i šei

Author:

Shurinov A. Yu.¹^ORCID,Borodavina E. V.¹^ORCID

Affiliation:

1. A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia

Abstract

Timeliness of accurate dynamic observation and a clear understanding of the treatment response guarantees health of patients with differentiated thyroid cancer. Multidimensional approach to evaluation of thyroid-stimulating hormone, tumor markers, ultrasound picture, as well as results of molecular imaging with radioactive iodine is clearly defined in international clinical guidelines. At the A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center for more than 15 years tactics of control exam 6 months after radioactive iodine ablation has been implemented. The aim of the current article is to consider the sequence of diagnostic search for different responses to treatment of differentiated thyroid cancer.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference72 articles.

1. Filetti S., Durante C., Hartl D., Leboulleux S. et al. Berruti on behalf of the ESMO Guidelines Committee. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(12):1856–83. DOI: 10.1093/ annonc/mdz400

2. Клинические рекомендации. Дифференцированный рак щитовидной железы. 2020 г. Доступно по: https://cr.minzdrav.gov. ru/schema/329_1#doc_a1. Clinical recommendations. Differentiated thyroid cancer. 2020 y. Available by: https://cr.minzdrav.gov.ru/schema/329_1#doc_a1. (In Russ.).

3. Gulec S., Ahuja S., Avram A. et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid 2021;31(7):1009–19. DOI: 10.1089/ thy.2020.0826

4. Haddad R., Bischoff L., Ball D. et al. Thyroid Carcinoma. Version 2.2022. NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Canc Netw 2022;20(8):925–51. DOI: 10.6004/ jnccn.2022.0040

5. Шуринов А.Ю., Крылов В.В., Бородавина Е.В. Радиойодаблация при раке щитовидной железы. Исторические и современные аспекты. Обзор литературы. Онкологический журнал: лучевая диагностика, лучевая терапия 2021;4(4):9–19. DOI: 10.37174/2587-7593-2021-4-4-9-19 Shurinov A.Yu., Krylov V.V., Borodavina E.V. Radioiodablation in thyroid cancer. Historical and modern aspects. Literature review. Onkologicheskij zhurnal: luchevaya diagnostika, luchevaya terapiya = Oncological Journal: radiation diagnostics, radiation therapy 2021;4(4):9–19. (In Russ.). DOI: 10.37174/2587-7593- 2021-4-4-9-19

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness;Head and Neck Tumors (HNT);2024-08-04

2. Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up;Head and Neck Tumors (HNT);2024-06-28